Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by D. Martín-García
Gene Mutations and Copy Number Alterations (Cna) Predict for Early Failure in Patients With Diffuse Large B-Cell Lymphoma (Dlbcl) Treated With R-Chop
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
Unfavorable Prognostic Impact of MYC Increased Copy Number (ICN) in Patients With Diffuse Large B-Cell (DLBCL) and High-Grade Lymphoma Treated With Immunochemotherapy
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Diffuse Large B-Cell Lymphoma Presenting With Gastrocolic Fistula and Successfully Treated With R-Chop Chemotherapy
Tenri Medical Bulletin
Multiplex Polymerase Chain Reaction-Based Prognostic Models in Diffuse Large B-Cell Lymphoma Patients Treated With R-Chop
British Journal of Haematology
Hematology
Blood Lymphocyte-To-Monocyte Ratio Identifies High-Risk Patients in Diffuse Large B-Cell Lymphoma Treated With R-Chop
PLoS ONE
Multidisciplinary
Increased MYC Gene Copy Number Correlates With Increased mRNA Levels in Diffuse Large B-Cell Lymphoma
Haematologica
Hematology
Identification of Gene Modules Associated With Survival of Diffuse Large B-Cell Lymphoma Treated With CHOP-based Chemotherapy
Pharmacogenomics Journal
Molecular Medicine
Genetics
Pharmacology
Tumor Necrosis as a Prognostic Factor of Diffuse Large B-Cell Lymphoma Treated With R-Chop Therapy
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Accept: A Phase Ib/Ii Combination of Acalabrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-Chop) for Patients With Diffuse Large B-Cell Lymphoma (Dlbcl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
MELK Serves as a Potent Independent Biomarker to Predict Survival of Diffuse Large B-Cell Lymphoma Patients Treated With Rituximab-Chop Regimen
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
